MO

Moogene Medi Co., Ltd.

Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.

322970 | KO

Overview

Corporate Details

ISIN(s):
KR7322970005
LEI:
Country:
South Korea
Address:
경기도 하남시 미사강변중앙로7번안길 25씨동 10층(풍산동,유-테크밸리씨타워), 하남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Moogene Medi Co., Ltd. is a biotechnology company specializing in nano-medicine and the development of advanced drug delivery systems. The company focuses on its Lipid Nanoparticle (LNP) carrier system platform to create safer and more effective methods for transporting various therapeutic agents, such as genes, chemicals, and proteins. Moogene Medi aims to address incurable and severe diseases by developing novel therapeutics based on optimized LNPs tailored to each drug's characteristics. The company provides end-to-end support, from research and development to clinical study manufacturing in its aseptic, GMP-grade facility, also offering assay services for its developed nano-carrier systems.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-18 00:00
Regulatory News Service
임상시험단계진입ㆍ종료(자율공시)
Korean 8.9 KB
2025-06-30 00:00
Report Publication Announcement
기업설명회(IR)개최결과
Korean 6.6 KB
2025-06-13 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 14.7 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 9.9 KB
2025-03-19 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 277.8 KB
2025-03-12 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 83.0 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 91.4 KB
2025-03-04 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.0 KB
2025-03-04 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-01-06 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-11-25 00:00
Report Publication Announcement
기업설명회(IR)개최결과
Korean 6.6 KB
2024-11-11 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2024-10-02 00:00
Regulatory News Service
기타주요경영사항(자율공시)
Korean 6.9 KB

Automate Your Workflow. Get a real-time feed of all Moogene Medi Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Moogene Medi Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Moogene Medi Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.